Literature DB >> 19157427

Appearance of dextranomer/hyaluronic Acid copolymer implants on computerized tomography after endoscopic treatment of vesicoureteral reflux in children.

Wolfgang H Cerwinka1, Jing Qian, Kirk A Easley, Hal C Scherz, Andrew J Kirsch.   

Abstract

PURPOSE: With the increasing popularity of endoscopic treatment for vesicoureteral reflux in children, dextranomer/hyaluronic acid copolymer implants are more frequently detected on computerized tomography, which may lead to misinterpretation and unnecessary intervention. The objective of this study was to characterize the long-term appearance of dextranomer/hyaluronic acid copolymer implants on computerized tomography.
MATERIALS AND METHODS: We evaluated the hospital charts of 893 patients who had undergone dextranomer/hyaluronic acid copolymer injection for vesicoureteral reflux between July 2001 and November 2007 to identify those who underwent subsequent computerized tomography of the abdomen and pelvis. A total of 30 patients with ureterovesical junction stones served as the control group. Seven patients who proceeded to extravesical reimplantation after failed endoscopic treatment had dextranomer/hyaluronic acid copolymer implants explanted and microscopically evaluated.
RESULTS: Of 893 patients who had undergone endoscopic treatment for vesicoureteral reflux 17 (1.9%) underwent subsequent computerized tomography. A total of 33 dextranomer/hyaluronic acid copolymer implants were detected on computerized tomography, and were classified as low density (21) or high density (12). Median density was 22 HU (range 15 to 27) for low density implants and 193 HU (126 to 367) for high density implants. Radiograph of the kidneys, ureters and bladder, and fluoroscopy did not visualize high density implants. Neither gender, age at endoscopic treatment, vesicoureteral reflux grade, hydrodistention grade, injection volume, success nor second injection was associated with a high density implant. Only elapsed time between surgery and computerized tomography was associated with increased implant density (p = 0.02).
CONCLUSIONS: Dextranomer/hyaluronic acid copolymer implants may be encountered on computerized tomography as low or high density lesions. History of vesicoureteral reflux and absence of hydronephrosis as well as hematuria should provide reassurance and prevent inappropriate intervention for misdiagnosed ureteral stones.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19157427     DOI: 10.1016/j.juro.2008.11.036

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.

Authors:  Ellen Shapiro
Journal:  Rev Urol       Date:  2008

2.  Imaging appearance of dextranomer/hyaluronic acid copolymer implant injections for treatment of velopharyngeal insufficiency.

Authors:  W Brinjikji; S A Cofer; J I Lane
Journal:  AJNR Am J Neuroradiol       Date:  2015-02-12       Impact factor: 3.825

3.  Endoscopic treatment of vesicoureteral reflux in children with subureteral dextranomer/hyaluronic acid injection: a single-centre, 7-year experience.

Authors:  Mihovil Biočić; Jakov Todorić; Dražen Budimir; Andrea Cvitković Roić; Zenon Pogorelić; Ivo Jurić; Tomislav Šušnjar
Journal:  Can J Surg       Date:  2012-10       Impact factor: 2.089

4.  Evaluation of pediatric nephrolithiasis.

Authors:  Paul J Kokorowski; Katherine Hubert; Caleb P Nelson
Journal:  Indian J Urol       Date:  2010-10

5.  Prevesical Calcification and Hydronephrosis in a Girl Treated for Vesicoureteral Reflux.

Authors:  Sarah Kuipers; Eric H J R van der Horst; Jonathan I M L Verbeke; Arend Bökenkamp
Journal:  Glob Pediatr Health       Date:  2016-06-13

6.  Dextranomer/Hyaluronic Acid Calcification Masquerading as Distal Ureteral Calculi in a Patient Previously Treated for Vesicoureteral Reflux.

Authors:  Muammer Bozkurt; Samir Agalarov; Erkan Merder; Fatih Altunrende
Journal:  J Endourol Case Rep       Date:  2018-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.